386 related articles for article (PubMed ID: 37119051)
21. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
22. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort.
Asmar KE; Fève B; Colle R; Gressier F; Vievard A; Trabado S; Verstuyft C; Haffen E; Polosan M; Ferreri F; Falissard B; Chanson P; Becquemont L; Corruble E
J Affect Disord; 2018 Dec; 241():22-28. PubMed ID: 30092445
[TBL] [Abstract][Full Text] [Related]
23. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
24. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
[TBL] [Abstract][Full Text] [Related]
25. Top 10 priorities for future infertility research: an international consensus development study† ‡.
Duffy JMN; Adamson GD; Benson E; Bhattacharya S; Bhattacharya S; Bofill M; Brian K; Collura B; Curtis C; Evers JLH; Farquharson RG; Fincham A; Franik S; Giudice LC; Glanville E; Hickey M; Horne AW; Hull ML; Johnson NP; Jordan V; Khalaf Y; Knijnenburg JML; Legro RS; Lensen S; MacKenzie J; Mavrelos D; Mol BW; Morbeck DE; Nagels H; Ng EHY; Niederberger C; Otter AS; Puscasiu L; Rautakallio-Hokkanen S; Sadler L; Sarris I; Showell M; Stewart J; Strandell A; Strawbridge C; Vail A; van Wely M; Vercoe M; Vuong NL; Wang AY; Wang R; Wilkinson J; Wong K; Wong TY; Farquhar CM; ; AlAhwany H; Balaban O; Barton F; Beebeejaun Y; Boivin J; Bosteels JJA; Calhaz-Jorge C; D’Angelo A; F. Dann L; J. De Jonge C; du Mez E; A. Ferriani R; Gerval MO; J. Gingel L; Greenblatt EM; Hartshorne G; Helliwell C; Hughes LJ; Jo J; Jovanović J; Kiesel L; Kietpeerakool C; Kostova E; Kucuk T; Kumar R; Lawrence RL; Lee N; Lindemann KE; Loto OM; Lutjen PJ; MacKinven M; Mascarenhas M; McLaughlin H; Mourad SM; Nguyen LK; Norman RJ; Olic M; Overfield KL; Parker-Harris M; Repping S; Rizzo R; Salacone P; Saunders CH; Sengupta R; Sfontouris IA; Silverman NR; Torrance HL; Uphoff EP; Wakeman SA; Wischmann T; Woodward BJ; Youssef MA
Hum Reprod; 2020 Dec; 35(12):2715-2724. PubMed ID: 33252677
[TBL] [Abstract][Full Text] [Related]
26. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
27. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Tran PT; Lowe K; Tsai HL; Song DY; Hung AY; Hearn JWD; Miller S; Proudfoot JA; Deek MP; Phillips R; Lotan T; Paller CJ; Marshall CH; Markowski M; Dipasquale S; Denmeade S; Carducci M; Eisenberger M; DeWeese TL; Orton M; Deville C; Davicioni E; Liauw SL; Heath EI; Greco S; Desai NB; Spratt DE; Feng F; Wang H; Beer TM; Antonarakis ES
J Clin Oncol; 2023 Feb; 41(6):1307-1317. PubMed ID: 36367998
[TBL] [Abstract][Full Text] [Related]
28. No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis.
Katalinic A; Noftz MR; Garcia-Velasco JA; Shulman LP; van den Anker JN; Strauss Iii JF
Hum Reprod Open; 2024; 2024(1):hoae004. PubMed ID: 38344249
[TBL] [Abstract][Full Text] [Related]
29. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
[TBL] [Abstract][Full Text] [Related]
30. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
31. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
[TBL] [Abstract][Full Text] [Related]
32. Endometriosis classification systems: an international survey to map current knowledge and uptake.
; Zondervan KT; Missmer S; Abrao MS; Einarsson JI; Horne AW; Johnson NP; Lee TTM; Petrozza J; Tomassetti C; Vermeulen N; Grimbizis G; De Wilde RL
Hum Reprod Open; 2022; 2022(1):hoac002. PubMed ID: 35237731
[TBL] [Abstract][Full Text] [Related]
33. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.
Humaidan P; Nelson SM; Devroey P; Coddington CC; Schwartz LB; Gordon K; Frattarelli JL; Tarlatzis BC; Fatemi HM; Lutjen P; Stegmann BJ
Hum Reprod; 2016 Sep; 31(9):1997-2004. PubMed ID: 27343272
[TBL] [Abstract][Full Text] [Related]
34. Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze).
Maheshwari A; Bell JL; Bhide P; Brison D; Child T; Chong HY; Cheong Y; Cole C; Coomarasamy A; Cutting R; Hardy P; Hamoda H; Juszczak E; Khalaf Y; Kurinczuk JJ; Lavery S; Linsell L; Macklon N; Mathur R; Pundir J; Raine-Fenning N; Rajkohwa M; Scotland G; Stanbury K; Troup S; Bhattacharya S
Hum Reprod; 2022 Mar; 37(3):476-487. PubMed ID: 34999830
[TBL] [Abstract][Full Text] [Related]
35. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
36. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
37. Current global status of male reproductive health.
De Jonge CJ; Barratt CLR; Aitken RJ; Anderson RA; Baker P; Chan DYL; Connolly MP; Eisenberg ML; Garrido N; Jørgensen N; Kimmins S; Krausz C; McLachlan RI; Niederberger C; O'Bryan MK; Pacey A; Priskorn L; Rautakallio-Hokkanen S; Serour G; Veltman JA; Vogel DL; Vazquez-Levin MH
Hum Reprod Open; 2024; 2024(2):hoae017. PubMed ID: 38699533
[TBL] [Abstract][Full Text] [Related]
38. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
39. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
